ProRx Pharma has announced the addition of six injectable products to its portfolio, aimed at supporting the growing demand ...

For the fiscal year 2025, Hikma has reiterated its guidance, expecting group revenue to grow between 4% and 6%, with core operating profit projected to be in the range of $730 million to $770 million.

Hims & Hers stock has dropped over 60% from its peak due to concerns about its GLP-1 business. Read why I think HIMS stock is ...

Researchers found that by December 2023, more than 1 in 3 of the medications being started for type 2 diabetes treatment were GLP-1RA-based medications.

As demand for GLP-1 medications surges, Hydreight’s inclusion of Liraglutide introduces a stable, patent-free, and clinically proven option—ideal for patients and providers seeking consistent ...

The telehealth company Hims & Hers is adding Zepbound and generic liraglutide to its offering of weight-loss drugs.

Research reveals GLP-1 receptor agonists influence gut microbiome, enhancing metabolic health and offering anti-inflammatory ...

The following is a summary of “Efficacy of 12 months therapy with glucagon-like peptide-1 receptor agonists liraglutide and ...

Cipla, Lupin and Takeda currently have alternative products available. Liraglutide injection: Multiple presentations of liraglutide injection, marketed under Victoza and Saxenda, are facing limited ...